Heparin-induced thrombocytopenia epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Epidemiology and demographics== | ==Epidemiology and demographics== | ||
===Prevalence=== | ===Prevalence=== | ||
*Worldwide, the prevalence of HIT ranges from a low of 200 per 100,000 persons to a high of | *Worldwide, the prevalence of HIT (in persons exposed to heparin) ranges from a low of 200 per 100,000 persons to a high of 5,000 per 100,000 persons.<ref name="pmid20059332">{{cite journal| author=Arepally GM, Ortel TL| title=Heparin-induced thrombocytopenia. | journal=Annu Rev Med | year= 2010 | volume= 61 | issue= | pages= 77-90 | pmid=20059332 | doi=10.1146/annurev.med.042808.171814 | pmc=4153429 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20059332 }} </ref><ref name="pmid25444534">{{cite journal| author=Obeng EA, Harney KM, Moniz T, Arnold A, Neufeld EJ, Trenor CC| title=Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. | journal=J Pediatr | year= 2015 | volume= 166 | issue= 1 | pages= 144-50 | pmid=25444534 | doi=10.1016/j.jpeds.2014.09.017 | pmc=4274245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25444534 }} </ref> | ||
*In pediatric populations, the prevalence of HIT (in persons exposed to heparin) ranges from a low of 1,500 per 100,000 persons to a high of 3,700 per 100,000 persons with an average prevalence of 2,600 per 100,000 persons.<ref name="pmid25444534">{{cite journal| author=Obeng EA, Harney KM, Moniz T, Arnold A, Neufeld EJ, Trenor CC| title=Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. | journal=J Pediatr | year= 2015 | volume= 166 | issue= 1 | pages= 144-50 | pmid=25444534 | doi=10.1016/j.jpeds.2014.09.017 | pmc=4274245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25444534 }} </ref> | |||
*In neonatal populations, the prevalence of HIT (in persons exposed to heparin) is as low as 330 per 100,000 persons.<ref name="pmid25444534">{{cite journal| author=Obeng EA, Harney KM, Moniz T, Arnold A, Neufeld EJ, Trenor CC| title=Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. | journal=J Pediatr | year= 2015 | volume= 166 | issue= 1 | pages= 144-50 | pmid=25444534 | doi=10.1016/j.jpeds.2014.09.017 | pmc=4274245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25444534 }} </ref> | |||
===Incidence=== | ===Incidence=== | ||
Revision as of 22:17, 9 July 2017
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia epidemiology and demographics |
|
FDA on Heparin-induced thrombocytopenia epidemiology and demographics |
|
CDC on Heparin-induced thrombocytopenia epidemiology and demographics |
|
Heparin-induced thrombocytopenia epidemiology and demographics in the news |
|
Blogs on Heparin-induced thrombocytopenia epidemiology and demographics |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2] Shyam Patel [3]
Overview
Heparin-induced thrombocytopenia (HIT) occurs in persons who are exposed to heparin or heparin-related products. The majority of medically or surgically hospitalized patients are exposure to heparin in some form, so the incidence of HIT can be quite high in these persons. The incidence of HIT is higher with certain type of heparin (such as bovine instead of porcine heparin) and in certain types of patients (such as surgical patients instead of obstetric or pediatric patients). There are no geographic or racial disparities in HIT, but it is known that HIT occurs more commonly in females compared to males.
Epidemiology and demographics
Prevalence
- Worldwide, the prevalence of HIT (in persons exposed to heparin) ranges from a low of 200 per 100,000 persons to a high of 5,000 per 100,000 persons.[1][2]
- In pediatric populations, the prevalence of HIT (in persons exposed to heparin) ranges from a low of 1,500 per 100,000 persons to a high of 3,700 per 100,000 persons with an average prevalence of 2,600 per 100,000 persons.[2]
- In neonatal populations, the prevalence of HIT (in persons exposed to heparin) is as low as 330 per 100,000 persons.[2]
Incidence
- Incidence is defined as the number of new cases per population in a given time period.
- The standard format to report the incidence is ___ per 100,000 individuals.
- When using numbers with decimal points, avoid reporting more than 1 number after the decimal point. For example, report a incidence as 10.1 instead of 10.09322. Many numbers after the decimal point may suggest a false sense of accuracy.
- You can pick one or more of the template sentences below for this section:
- Worldwide, the incidence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
- Worldwide, the incidence of (insert disease state here) is _____ per 100,000 persons.
- In developed countries, the incidence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
- In developed countries, the incidence of (insert disease state here) is _____ per 100,000 persons.
- In developing countries/ Africa, the incidence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
- In developing countries/ Africa, the incidence of (insert disease state here) is _____ per 100,000 persons.
- In ____ (insert year), the incidence of _______ (insert disease name) was estimated to be _______ (insert number) cases per 100,000 individuals worldwide.
Case Fatality Rate
- The case fatality rate is defined the number of deaths (fatality) among patients with the disease (case). Case fatality rate should be distinguished from "Mortality Rate" (defined as the number of deaths among the at-risk population).
- The case fatality rate is usually described as a function of time (e.g. In 2015 / annually etc...).
- When using numbers with decimal points, avoid reporting more than 1 number after the decimal point. For example, report the case fatality rate as 10.1% instead of 10.09322%. Many numbers after the decimal point may suggest a false sense of accuracy.
- You can pick the template sentence below for this section:
- In ____ (year), the case fatality rate of ____ (disease name) is ____ (case fatality rate in %).
- The annual case fatality rate of ____ (disease name) is approximately ____ (case fatality rate in %).
Age
- This section can describe the impact of the disease depending on the persons age, and the age-specific prevalence and incidence.
- The prevalence of ____ (insert disease state here) increases/decreases with age.
- _____ (insert acute disease) commonly affects _____ (insert age group).
- _____ (insert chronic disease) is usually first diagnosed among _____ (insert age group).
Gender
This section describe how prevalence of the disease varies by gender. When describing male to female ratios with decimal points, avoid reporting more than 1 number after the decimal point. For example, report a ratio as as 1.5 to 1 instead of 1.48294 to 1. Many numbers after the decimal point may suggest a false sense of accuracy. You can use either of the following template sentences:
- ______ (insert gender 1) are more commonly affected with ______ (insert disease name) than _____ (insert gender 2). The _____ (insert gender ratio e.g. male to female) ratio is approximately _____ (insert number > 1) to 1.
- The prevalence and incidence of (insert disease state here) does not vary by gender.
- Men and women are affected equally by (insert disease name here).
- (Insert disease state here) is more prevalent in men women.
- The prevalence of (insert disease state here) among men is ____ per 100,000, while it is _____ per 100,000 among women.
- The incidence of (insert disease state here) among men is ____ per 100,000, while it is _____ per 100,000 among women.
Race
This section describes how the disease differs based upon race. You can use the following template sentence for this section:
- The prevalence of _____ (insert disease) does not vary by race.
- (Insert disease state here) is more prevalent in the ____ (inser race) race and ____ (insert other race) races.
- There is no racial predilection for ____ (insert disease name)
- _____ (insert disease) usually affects individuals of the _____ (inser race) race. _____ (insert other race) individuals are less likely to develop ______ (disease name).
Developed Countries
- In this section you should describe the impact of the disease in developed countries.
- Incidence, prevalence, and geographical distribution or areas of interest can be mentioned, as well as the relevant impact the disease has on society.
Developing Countries
- In this section you should describe the impact of the disease in developing countries.
- Incidence, prevalence, and geographical distribution or areas of interest can be mentioned, as well as the relevant impact the disease has on society.
Reference
- ↑ Arepally GM, Ortel TL (2010). "Heparin-induced thrombocytopenia". Annu Rev Med. 61: 77–90. doi:10.1146/annurev.med.042808.171814. PMC 4153429. PMID 20059332.
- ↑ 2.0 2.1 2.2 Obeng EA, Harney KM, Moniz T, Arnold A, Neufeld EJ, Trenor CC (2015). "Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system". J Pediatr. 166 (1): 144–50. doi:10.1016/j.jpeds.2014.09.017. PMC 4274245. PMID 25444534.